GPX4 and breast carcinoma: used breast cancer cell lines (HS578t and MDA-MB-231) and found that the expression of GPX4 was increased in gefitinib-resistant cells, and when GPX4 was silenced, the expression of intracellular malignant malonaldehyde (MDA) and ROS increased and the expression of glutathione (GSH) decreased, which promoted the ferroptosis of cells, and then increased the sensitivity of cells to gefitinib (10).